Rheumatoid arthritis: New approaches for its evaluation and management

Archives of Physical Medicine and Rehabilitation

Volumn 76, Issue 2, 1995, Pages 190-201

  Semble, Elliott L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DICLOFENAC; GAMMA INTERFERON; GOLD SALT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; METHOTREXATE; METHYLPREDNISOLONE; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PREDNISONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SUCRALFATE; SULINDAC;

BONE MARROW TOXICITY; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; EXERCISE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL SUPPORT; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PHYSICAL DISABILITY; PHYSIOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; SKIN TOXICITY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; EXERCISE THERAPY; HEALTH STATUS INDICATORS; HUMANS; MAGNETIC RESONANCE IMAGING; METHOTREXATE;

EID: 0028852477     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(95)80029-8     Document Type: Review

References (144)

1. What is the natural history of rheumatoid arthritis?
2. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
3. General aspects of differential diagnosis
4. Clinical features of rheumatoid arthritis
5. Bacterial arthritis
6. Acute infectious arthritis
7. Gonococcal and meningococcal arthritides
8. Infectious arthritis
9. Human parvovirus B19 arthropathy in two adults after contact with childhood erythema infectiosum
10. Still's disease in the adult
11. Disease activity in rheumatoid arthritis: preliminary report of the Consensis Study Group of the European Workshop for Rheumatology Research
12. An electronic method for measuring joint tenderness in rheumatoid arthritis
13. Strength and function in the normal and rheumatoid hand
14. Laboratory evaluation of inflammation
15. The relation of radiographic changes to serum acute-phase proteins in 200 patients with rheumatoid arthritis
16. Short-term effects of low-dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis
17. Efficacy of tests used to monitor rheumatoid arthritis
18. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome
19. Onset, early stages and prognosis in rheumatoid arthritis: a clinical study of 200 patients with 11-year follow-up
20. Clinical significance of rheumatoid factors in early rheumatoid arthritis results of a follow-up study
21. Prognostic factors radiographic damage and physical disability in early rheumatoid arthritis
22. Long-term outcome of treating rheumatoid arthritis: results after 20 years
23. Sensitivity of radiographic changes of hand and foot joints as a diagnostic criteria in patients with rheumatoid arthritis
24. The radiographic criterion in the 1987 revised criteria for rheumatoid arthritis; reassessment in a prospective study of early disease
25. Biannual radiographic assessments of hands and feet in a three-year perspective follow up of patients with early rheumatoid arthritis
26. Magnetic resonance imaging in patients with inflammatory arthritis of the knee
27. Magnetic resonance imaging of the craniovertebral junction in rheumatoid arthritis
28. Detection of flexor tenosynovitis by magnetic resonance imaging: its relationship to diurnal variation of symptoms
29. MR imaging of rheumatoid hand lesions: comparison with conventional radiology in 31 patients
30. MRI of the cervical spine: rheumatoid arthritis compared with cervical spondytosis
31. Nuclear medicine, and special radiologic imaging and technique in the diagnosis of rheumatic diseases
32. Predictive value of radionuclide joint scintigrams
33. The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
34. THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
35. Measuring health status in arthritis: the arthritis impact measure scales
36. AIMS 2: the content and properties of revised and expanded arthritis impact measurement scales health status questionnaire
37. Measurement of patient outcome in arthritis
38. Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaire
39. The dimensions of health outcomes: the Health Assessment Questionnaire Disability and Pain Scales
40. Measurement of functional status, quality of life, and utility in rheumatoid arthritis
41. Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict long-term morbidity and mortality in rheumatoid arthritis
42. Functional status indices: reliability of a chronic disease evaluation instrument
43. Comprehensive outpatient care in rheumatoid arthritis
44. Studies of illness in the aged: The index of ADL: a standardized measure of biological and psychosocial function
45. Health care research in rheumatology
46. Concordance between clinical and patient assessment of physical and mental health status
47. Functional disability in rheumatoid arthritis: two different models in early and established disease
48. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
49. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparisons with rheumatoid arthritis
50. Work disability in rheumatoid arthritis: effects of disease, social, and work factors
51. A comparison of disability by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female outpatients
52. The assessment and prediction of functional disability in rheumatoid arthritis
53. Long-term outcome in rheumatoid arthritis
54. Early rheumatoid arthritis-onset, course, and outcome over 2 years
55. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis
56. Education level and rheumatoid arthritis; evidence from five data centers
57. Occupation, income and education as independent covariates of arthritis in four national probability samples
58. The importance of age, education, and comorbidity in the substantial earnings loss of individuals with symmetric polyarthritis
59. Analysis of methotrexate treatment effect in a longitudinal observational study: utility of cluster analysis
60. Cost effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis
61. Comprehensive management of patients with rheumatoid arthritis. Some results of the Regional Arthritis Central Program in Michigan
62. Anti-inflammatory drugs and gastric mucosal damage
63. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents
64. Liver disease induced by non-steroidal anti-inflammatory drugs
65. Neurological complications of non-steroidal anti-inflammatory drugs
66. NSAID gastropathy: the second most deadly rheumatic disease?
67. The association of non-steroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding
68. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
69. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside
70. The relative gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs
71. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs
72. The spectrum of adverse gastrointestinal effects associated with non-steroidal anti-inflammatory drugs
73. Salsalate in the treatment of rheumatoid arthritis: a double-blind clinical and gastroscopic trial versus piroxicam II. Endoscopic evaluation
74. Preclinical overview of nabumetone: pharmacology, bioavailability, metabolism, and toxicology
75. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving non-steroidal anti-inflammatory drugs
76. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs
77. Effect of ranitidine on gastroduodenal mucosal damage induced by non-steroidal anti-inflammatory drugs
78. 2 receptor antagonists: a controlled clinical trial
79. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage
80. Renal and cardiovascular adverse effects of nonsteroidal anti-inflammatory drugs
81. Implications of non-steroidal anti-inflammatory drug therapy
82. Diclofenac-associated hepatotoxicity
83. Cognitive dysfunction associated with naproxen and Ibuprofen in the elderly
84. Sulfasalazine
85. Gold and antimalarial therapy
86. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts
87. Long-term treatment of rheumatoid arthritis with sulfasalazine, gold, or penicillamine
88. Meta-analysis of injectable gold in rheumatoid arthritis
89. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
90. Gold compounds in the rheumatic diseases
91. Methotrexate
92. Methotrexate for rheumatoid arthritis
93. Methotrexate in rheumatoid arthritis
94. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate
95. Treatment of rheumatoid arthritis
96. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis
97. Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy
98. Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study
99. Does steroid pulsing influence the efficacy and toxicity of chrysotherapy?
100. Treatment of rheumatoid arthritis
101. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis
102. Intractable rheumatoid arthritis: treatment with combined cyclophosphamide, azathioprine and hydroxychloroquine
103. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydrochloroquine: a follow-up study
104. Combination chemotherapy for severe rheumatoid arthritis
105. The combined use of methotrexate and intramuscular gold in rheumatoid arthritis
106. Remodeling the pyramid: a concept whose time has come
107. New approaches to the management of rheumatoid arthritis
108. Immunotherapy, past, present and future
109. New inflammatory mediators and therapeutic agents: cytokines in rheumatoid arthritis
110. Efficacy of total lymph node irradiation in intractable rheumatoid arthritis: a double-blind randomized trial
111. Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis
112. Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage
113. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody
114. Treatment of rheumatoid arthritis with single-dose or weekly pulses of chimeric anti-CD4 monoclonal antibody
115. Preliminary report
116. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis
117. Double-blind trial of recombinant gamma interferon versus placebo in the treatment of rheumatoid arthritis
118. A double-blind study comparing human interferon gamma and placebo
119. Application of the polymerase chain reaction and immunofluorescence techniques to the detection of bacteria inYersinia-triggered reactive arthritis
120. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
121. Cyclosporin A treatment of refractory rheumatoid arthritis
122. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study
123. Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine
124. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis
125. Physical training in rheumatoid arthritis: a controlled long-term study. II. Functional capacity and general attitudes
126. Physical training in rheumatoid arthritis, a controlled long-term study
127. Exercise and arthritis
128. The role of exercise in the treatment of inflammatory arthritis
129. Essentials of physical management and rehabilitation in arthritis
130. Exercise for arthritis
131. Diet therapy for rheumatoid arthritis
132. Food induced (“allergic”) arthritis: clinical and serological studies
133. Is there a role for diet or other questionable therapies in managing rheumatic diseases?
134. The controversy over zinc sulphate efficacy in rheumatoid and psoriatic arthritis
135. Food for thought, but not for arthritis
136. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis
137. Treatment of rheumatoid arthritis with gammalinolenic acid
138. Arthritis patient education: A review of the literature
139. Correlates of community resource information needs of arthritis patients
140. Assessing the impact of self-efficacy beliefs on adaption to rheumatoid arthritis
141. Coping strategies and affect in rheumatoid and psoriatic arthritis relationship to pain and disability
142. Evaluation of a computerbased education lesson for patients with systemic lupus erythematosus